Pfizer Makes Vaccines Entry With PowderMed Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition of the U.K. company will give Pfizer a pipeline of DNA-based vaccines that could surpass cell-based technology, firm says.
You may also be interested in...
GSK Spins Out Pain Assets, Raises $35.4m
UK-based Convergence's lead asset starts Phase II in neuropathic pain
GSK Spins Out Pain Assets, Raises $35.4m
UK-based Convergence's lead asset starts Phase II in neuropathic pain
Pfizer Plans Four New Products A Year Starting In 2011
Company highlights strength of pipeline at R&D briefing, but says it will rely on a near-term licensing strategy to address “gaps.”